Literature DB >> 2832198

Prolonged morphine treatment increases rat brain dihydropyridine binding sites: possible involvement in development of morphine dependence.

V Ramkumar1, E E el-Fakahany.   

Abstract

Regulation of L-type Ca2+ channels by morphine in rat brain was determined by the binding of [3H]nimodipine. Morphine, administered by subcutaneous pellet implantation, increased the density of [3H]nimodipine binding sites in a time- and dose-dependent manner and this effect was reversible upon removal of the pellets. Increases in these dihydropyridine sites were localized to the cortex, hippocampus, hypothalamus and brainstem but not to the cerebellum and striatum. Additional experiments were performed to test the ability of different Ca2+ channel antagonists to affect naloxone-precipitated withdrawal in morphine-dependent mice and rats. These drugs effectively reduced the incidence of naloxone-induced jumping in mice and several of the withdrawal signs in rats. Taken together, our study underscores the plasticity of brain L-type Ca2+ channels and suggests that their upregulation might contribute to morphine dependence.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2832198     DOI: 10.1016/0014-2999(88)90488-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  22 in total

1.  Involvement of the cyclic AMP system in the switch from tolerance into supersensitivity to the antinociceptive effect of the opioid sufentanil.

Authors:  M A Hurlé; I Goirigolzarri; E M Valdizán
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

2.  Differential effects of L-type calcium channel blockers and stimulants on naloxone-precipitated withdrawal in mice acutely dependent on morphine.

Authors:  M Barrios; J M Baeyens
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Study of the intraplantar injection of lidocaine and morphine on pain perception and the influence of morphine dependence and withdrawal on lidocaine-induced analgesia in rats.

Authors:  Taraneh Moini Zanjani; Masoumeh Sabetkasaei
Journal:  Iran Biomed J       Date:  2010-10

4.  Calcium channel blockers: effect on morphine-induced hypermotility.

Authors:  M I Martin; I Lizasoain; J C Leza
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Effect of repetitive electroconvulsive treatment on sensitivity to pain and on [3H]nitrendipine binding sites in cortical and hippocampal membranes.

Authors:  L Antkiewicz-Michaluk; J Michaluk; I Romańska; J Vetulani
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

6.  Calcium channel activation and self-biting in mice.

Authors:  H A Jinnah; S Yitta; T Drew; B S Kim; J E Visser; J D Rothstein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

7.  Reduction of morphine dependence and potentiation of analgesia by chronic co-administration of nifedipine.

Authors:  L Antkiewicz-Michaluk; J Michaluk; I Romańska; J Vetulani
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Effects of prototypic calcium channel blockers in methadone-maintained humans responding under a naloxone discrimination procedure.

Authors:  Alison Oliveto; Michael Mancino; Nichole Sanders; Christopher Cargile; J Benjamin Guise; Warren Bickel; W Brooks Gentry
Journal:  Eur J Pharmacol       Date:  2013-03-21       Impact factor: 4.432

9.  Concurrent nimodipine attenuates the withdrawal signs and the increase of cerebral dihydropyridine binding after chronic morphine treatment in rats.

Authors:  A Zharkovsky; A M Tötterman; J Moisio; L Ahtee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-05       Impact factor: 3.000

10.  Modulation of kappa-opioid receptor mediated tolerance in the guinea-pig ileum by chronic co-administration of dihydropyridines.

Authors:  J V Garaulet; M L Laorden; M V Milanés
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-06       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.